Recon: BMS inks $380M CAR-T manufacturing deal with Cellares – RAPS

The PTO Says LYTGOBI Patent is Ineligible for PTE Because of Untimely Application . . . And a Corrected NDA Approval Letter is No Saving Grace (FDA …